-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Muscle Invasive Bladder Cancer (MIBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Muscle Invasive Bladder Cancer (MIBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Muscle Invasive Bladder Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Bladder Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Epithelial Ovarian Cancer Drug Details: Enfortumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Fallopian Tube Cancer Drug Details: Enfortumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Peritoneal Cancer Drug Details: Enfortumab vedotin (Padcev)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zocaglusagene Nuzaparvovec in Pompe Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zocaglusagene Nuzaparvovec in Pompe Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zocaglusagene Nuzaparvovec in Pompe Disease Drug Details: Zocaglusagene nuzaparvovec (AT-845)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramosetron in Fecal Incontinence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramosetron in Fecal Incontinence report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramosetron in Fecal Incontinence Drug Details: Ramosetron (Nasea, Irribow) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-8374 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-8374 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ASP-8374...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-4396 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-4396 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-4396 in Solid Tumor Drug Details: ASP-4396 is under development for...